World Health Organization Sounds Concern Over Severe Lack of Weight-Loss Jabs
Under one in 10 people that would benefit from obesity jabs including Wegovy can access them, caution the WHO as it releases its first advice on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for more widespread and fairer access to these injectable treatments.
According to projections, more than two billion will be obese by 2030 if no action is taken.
"Our latest guidance acknowledges that excess weight is a chronic disease that can be treated with comprehensive and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key obstacles to widespread availability to the treatments that can aid individuals in losing considerable body mass, notes the agency.
Weight-Loss Drug Supply Crisis
Even under the current most favorable scenario, the production of these medications would only suffice for about 100 million people – under 10% of the global need, as stated by the health organization.
The advice urges nations and manufacturers to expand access, via strategies like patent sharing.
The intellectual property rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
The Way Weight-Loss Drugs Function
The injections mimick a natural hormone to slow digestion, curb appetite and increase satiety so users reduce food intake.
Patients commonly begin shedding pounds within a few weeks of commencing the regular doses.
Evidence points to people may put most of the weight back on after a year of halting the treatment, as their normal food cravings return.
To be carrying excess weight raises your likelihood for experiencing health problems, such as diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight impacts individuals in all nations and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
